Cervical AdenocarcinomaNCT01649089
Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer
A study testing Conization, Quality-of-Life Assessment and Questionnaire Administration in people with Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, run by GOG Foundation at 185 sites in 3 countries.
Trial summary
This clinical trial studies the physical function and quality-of-life before and after surgery in patients with stage I cervical cancer. Studying quality-of-life in patients undergoing surgery for cervical cancer may help determine the intermediate-term and long-term effects of surgery. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma
- What is being tested?
- Conization, Quality-of-Life Assessment and Questionnaire Administration
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 224 participants
- Where
- 185 sitesin 3 countries
- Study dates
- 5 Jun 2013to 1 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must consent for the appropriate surgery
- Patients with a histologic diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix, stage IA1 (lymph-vascular space invasion [LVSI]+), IA2, and IB1 (tumor size [maximum visible or palpable]) =< 2 cm), any grade
- All patients must have undergone a cone biopsy or loop electrosurgical excision procedure (LEEP); depth of invasion must be =< 10 mm
- Patients must have no evidence of metastasis on positron emission tomography (PET) scan or magnetic resonance imaging (MRI) or computed tomography (CT) scan of the pelvis and chest imaging
- Patients who have met the pre-entry requirements
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patient must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
Who cannot join
- Patients with stage IA1 disease who are LVSI negative
- Patients with stage IB1 with tumor size (maximum visible or palpable) > 2 cm
- Patients with >= stage IB2 disease
- Patients with clear cell or neuroendocrine cell types
- Patients with depth of invasion > 10 mm on first cone biopsy (or LEEP)
- Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
Trial locations and contacts
185 sites in 3 countries.
185 sites in 3 countries
United States174 sites
Jefferson Abington Hospital
Abington, Pennsylvania, 19001
Summa Health System - Akron Campus
Akron, Ohio, 44304
Sutter Auburn Faith Hospital
Auburn, California, 95602
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, 95603
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
Hematology/Oncology Clinic PLLC
Baton Rouge, Louisiana, 70809
Woman's Hospital
Baton Rouge, Louisiana, 70817
Strecker Cancer Center-Belpre
Belpre, Ohio, 45714
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, 94704
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Mills-Peninsula Medical Center
Burlingame, California, 94010
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, 95682
Aultman Health Foundation
Canton, Ohio, 44710
Eden Hospital Medical Center
Castro Valley, California, 94546
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Adena Regional Medical Center
Chillicothe, Ohio, 45601
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
Case Western Reserve University
Cleveland, Ohio, 44106
Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Mount Carmel East Hospital
Columbus, Ohio, 43213
Columbus Oncology and Hematology Associates Inc
Columbus, Ohio, 43214
Riverside Methodist Hospital
Columbus, Ohio, 43214
Grant Medical Center
Columbus, Ohio, 43215
The Mark H Zangmeister Center
Columbus, Ohio, 43219
Mount Carmel Health Center West
Columbus, Ohio, 43222
Doctors Hospital
Columbus, Ohio, 43228
Memorial Sloan Kettering Commack
Commack, New York, 11725
Mercy Hospital
Coon Rapids, Minnesota, 55433
Baptist Health Corbin
Corbin, Kentucky, 40701
Parkland Memorial Hospital
Dallas, Texas, 75235
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390
Sutter Davis Hospital
Davis, California, 95616
Grandview Hospital
Dayton, Ohio, 45405
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Delaware Radiation Oncology
Delaware, Ohio, 43015
Grady Memorial Hospital
Delaware, Ohio, 43015
Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Dublin Methodist Hospital
Dublin, Ohio, 43016
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Palo Alto Medical Foundation-Fremont
Fremont, California, 94538
Unity Hospital
Fridley, Minnesota, 55432
Central Ohio Breast and Endocrine Surgery
Gahanna, Ohio, 43230
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Mount Carmel Grove City Hospital
Grove City, Ohio, 43123
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
Sudarshan K Sharma MD Limited-Gynecologic Oncology
Hinsdale, Illinois, 60521
Queen's Medical Center
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Memorial Hermann Texas Medical Center
Houston, Texas, 77030
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Mercy Hospital Joplin
Joplin, Missouri, 64804
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
UC San Diego Moores Cancer Center
La Jolla, California, 92093
Fairfield Medical Center
Lancaster, Ohio, 43130
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89106
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Baptist Health Lexington
Lexington, Kentucky, 40503
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Saint Rita's Medical Center
Lima, Ohio, 45801
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky, 42431
Cancer Center of Kansas-Manhattan
Manhattan, Kansas, 66502
OhioHealth Mansfield Hospital
Mansfield, Ohio, 44903
Fairview Clinics and Surgery Center Maple Grove
Maple Grove, Minnesota, 55369
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Marietta Memorial Hospital
Marietta, Ohio, 45750
OhioHealth Marion General Hospital
Marion, Ohio, 43302
Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio, 44124
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
Jackson Memorial Hospital-Holtz Children's Hospital
Miami, Florida, 33136
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Memorial Medical Center
Modesto, California, 95355
Monongalia Hospital
Morgantown, West Virginia, 26505
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Palo Alto Medical Foundation-Camino Division
Mountain View, California, 94040
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, 94040
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
Tulane University Health Sciences Center
New Orleans, Louisiana, 70112
Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Licking Memorial Hospital
Newark, Ohio, 43055
Newark Radiation Oncology
Newark, Ohio, 43055
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868
AdventHealth Orlando
Orlando, Florida, 32803
Baptist Health Paducah
Paducah, Kentucky, 42003
Palo Alto Medical Foundation Health Care
Palo Alto, California, 94301
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Mercy Health Perrysburg Cancer Center
Perrysburg, Ohio, 43551
Cancer Center at Saint Joseph's
Phoenix, Arizona, 85004
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida, 33324
Southern Ohio Medical Center
Portsmouth, Ohio, 45662
Naval Medical Center - Portsmouth
Portsmouth, Virginia, 23708-2197
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Women and Infants Hospital
Providence, Rhode Island, 02905
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
University of Rochester
Rochester, New York, 14642
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California, 95661
Sutter Roseville Medical Center
Roseville, California, 95661
Sutter Medical Center Sacramento
Sacramento, California, 95816
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
California Pacific Medical Center-Pacific Campus
San Francisco, California, 94115
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California, 95065
Sutter Pacific Medical Foundation
Santa Rosa, California, 95403
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Baystate Medical Center
Springfield, Massachusetts, 01199
Mercy Hospital Springfield
Springfield, Missouri, 65804
CoxHealth South Hospital
Springfield, Missouri, 65807
Saint Louis Cancer and Breast Institute-South City
St Louis, Missouri, 63109
Mercy Hospital Saint Louis
St Louis, Missouri, 63141
Lakeview Hospital
Stillwater, Minnesota, 55082
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California, 94086
Olive View-University of California Los Angeles Medical Center
Sylmar, California, 91342
ProMedica Flower Hospital
Sylvania, Ohio, 43560
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo, Ohio, 43606
Saint Vincent Mercy Medical Center
Toledo, Ohio, 43608
Mercy Health - Saint Anne Hospital
Toledo, Ohio, 43623
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma, 74146
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
Sutter Cancer Centers Radiation Oncology Services-Vacaville
Vacaville, California, 95687
Sutter Solano Medical Center/Cancer Center
Vallejo, California, 94589
MD Anderson Cancer Center at Cooper-Voorhees
Voorhees Township, New Jersey, 08043
Ridgeview Medical Center
Waconia, Minnesota, 55387
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois, 60555
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
UW Cancer Center at ProHealth Care
Waukesha, Wisconsin, 53188
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Aurora West Allis Medical Center
West Allis, Wisconsin, 53227
Saint Ann's Hospital
Westerville, Ohio, 43081
Associates In Womens Health
Wichita, Kansas, 67208
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, 67208
Ascension Via Christi Hospitals Wichita
Wichita, Kansas, 67214
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67214
Rice Memorial Hospital
Willmar, Minnesota, 56201
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, 19090
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
Fairview Lakes Medical Center
Wyoming, Minnesota, 55092
Genesis Healthcare System Cancer Care Center
Zanesville, Ohio, 43701
South Korea10 sites
Gachon University Gil Hospital
Incheon, 405-760
Seoul National University Bundang Hospital
Seongnam, Kyeonggi-do, 463-707
Samsung Medical Center
Seoul, Korea, 135-710
Catholic University of Korea-Seoul Saint Mary's Hospital
Seoul, Korea, 137-040
Asan Medical Center
Seoul, 05505
Gangnam Severance Hospital
Seoul, 06273
Seoul National University Hospital
Seoul, 110-744
Yonsei University Health System-Severance Hospital
Seoul, 120-752
Kyung Hee University Hospital at Gangdong
Seoul, 134-727
Korea Cancer Center Hospital
Seoul, 139-706
Canada1 site
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
About this study
Official title: Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
This clinical trial studies the physical function and quality-of-life before and after surgery in patients with stage I cervical cancer. Studying quality-of-life in patients undergoing surgery for cervical cancer may help determine the intermediate-term and long-term effects of surgery.
Read the detailed description
PRIMARY OBJECTIVES:
- To examine the changes before and after non-radical surgical treatment (simple hysterectomy or cone biopsy [fertility preservation] and pelvic lymphadenectomy) on functional outcomes of bladder, bowel, and sexual function for stage IA1 (lymphatic vessel invasion positive [LVSI+]) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
II. To evaluate incidence and severity of lymphedema after non-radical surgery (simple hysterectomy or cone biopsy [fertility preservation] and pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
SECONDARY OBJECTIVES:
- To investigate if non-radical surgery (simple hysterectomy or cone biopsy [fertility preservation] with pelvic lymphadenectomy) demonstrates greater physical function and less toxicity in comparison to historical data on radical surgery (radical hysterectomy or radical trachelectomy).
II. To evaluate incidence and severity of treatment-related adverse events, including surgical complications, among the entire cohort and by treatment type.
III. To evaluate changes in quality of life (QOL) (Functional Assessment of Cancer Therapy-Cervix [FACT-Cx]), cancer worries (Impact of Events Scale [IES]) and sexual (Female Sexual Function Index [FSFI])/reproductive concerns (RCS) among the entire cohort and by treatment type.
IV. To explore relationships (correlation, interaction, independence) between functional outcomes (i.e., bladder function, bowel function, sexual function), adverse events (including and surgical complication lymphedema [Gynecologic Cancer Lymphedema Questionnaire (GCLQ)]), cancer worry (IES), surgical complications, and overall quality of life (FACT-Cx).
- To determine participants' intention for conception \& fertility rates (Integrative Care for Fertility [ICF]) and assess the reproductive concerns (RCS) of women following cone biopsy and pelvic lymphadenectomy for stage IA1 (LVSI+) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
VI. To estimate the efficacy of non-radical surgery (simple hysterectomy or cone biopsy [fertility preservation] and pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
OUTLINE:
Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
Patients complete the FACT-Cx, the IES, the FSFI, the GCLQ, and the Patient Reported Outcomes Measurement Information System (PROMIS) questionnaires at baseline, 4-6 weeks after surgery, and then every 6 months for 3 years. Patients undergoing cone biopsy and pelvic lymphadenectomy also complete the ICF and RCS questionnaires.
After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months for 1 year, and then every 6 months for 2 years.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Lymphedema, Stage IA1 Cervical Cancer AJCC v6 and v7, Stage IA2 Cervical Cancer AJCC v6 and v7
- Being tested
- Conization, Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery, Therapeutic Lymphadenectomy
- Medical subject headings
- Lymphedema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ConizationProcedure or surgery
Also called cone biopsy, Cone Biopsy of Cervix, Conization of Cervix, Conization of Uterine Cervix
Undergo cone biopsy
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Therapeutic Conventional SurgeryProcedure or surgery
Undergo hysterectomy
Therapeutic LymphadenectomyProcedure or surgery
Undergo lymphadenectomy
| Study group | Role | What they receive |
|---|---|---|
| Treatment (cone biopsy/lymphadenectomy or hysterectomy) | Experimental | Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy. Receives: Procedure: Conization; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Therapeutic Conventional Surgery; Procedure: Therapeutic Lymphadenectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in bladder and bowel function score based on supplemental bladder and bowel questions plus 4 items from the Functional Assessment of Cancer Therapy-Cervix (3 bladder and 1 bowel question)
Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Measured: Baseline to 3 years
Change in sexual function and activity based on Female Sexual Function Index (19 items) score plus 2 Patient Reported Outcomes Measurement Information System screener items
Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Measured: Baseline to 3 years
Lymphedema
Based on Cancer Lymphedema Questionnaire score.
Measured: Up to 3 years
Maximum grade and duration of severe adverse events associated with bladder, bowel, and sexual dysfunction and lymphedema
Graded according to Common Terminology Criteria for Adverse Events version 4.0 (version 5.0 will be used staring April 1, 2018).
Measured: Up to 3 years after non-radical surgical procedure
Secondary outcomes (7)
Maximum grade of treatment-related adverse events
Graded according to Common Terminology Criteria for Adverse Events version 4.0 (version 5.0 will be used staring April 1, 2018).
Measured: Up to 30 days after surgical procedure
Change in overall quality of life
Will be assessed based on Functional Assessment of Cancer Therapy-Cervix (15 items) score. Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Measured: Baseline to 3 years
Change in cancer worries based on Impact of Events score
Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Measured: Baseline to 3 years
Change in reproductive concerns based on reproductive concerns (14 items) score
Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Measured: Baseline to 3 years
Site of first recurrence
Classified as either local (pelvis regions, including vaginal) or distant (abdomen, lung, bone, brain, and other).
Measured: Up to 3 years
Recurrence-free survival
Product-limit estimates according to the method of Kaplan and Meier will be used to estimate recurrence-free survival. In addition, Cox proportional hazard regression will be employed to evaluate relative risk (hazard ratio) adjusting for known prognostic factors. Trellis plots will be used to display point estimates of hazard ratio and respective 95% confidence intervals from subgroup analyses. Local recurrence will be summarized using frequency tables and plot of cumulative incidence of local recurrence over time.
Measured: Up to 3 years
Overall survival
Product-limit estimates according to the method of Kaplan and Meier will be used to estimate overall survival. In addition, cox proportional hazard regression will be employed to evaluate relative risk (hazard ratio) adjusting for known prognostic factors. Trellis plots will be used to display point estimates of hazard ratio and respective 95% confidence intervals from subgroup analyses. Gompertz hazard regression will also be employed to evaluate relative risk (hazard ratio) and cure rates, adjusting for known prognostics factors.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2012 (estimated)
- Study start5 Jun 2013
- Primary completion1 Dec 2024 (estimated)
- Study completion1 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cervical AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 224 participants (estimated)
Sponsor and investigators
- Lead sponsor
- GOG Foundation
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Allan L Covens, Principal investigator, NRG Oncology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01649089
- Sponsor's protocol ID
- GOG-0278
- Other IDs
- NCI-2012-01990, CDR0000737208, GOG-0278, GOG-0278, GOG-0278, U10CA101165, U10CA180868, UG1CA189867
- Status last verified
- May 2024
- First submitted
- 21 Jul 2012
- Last updated
- 3 May 2024
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Boisen M, Guido R. Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer. Clin Obstet Gynecol. 2023 Sep 1;66(3):500-515. doi: 10.1097/GRF.0000000000000790. Epub 2023 Jul 25.
PubMed 37650664
Study at a glance
From the registry record, last updated by the sponsor on 3 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
- ClinicalTrials.gov ID
- NCT01649089
- Acronym / sponsor ID
- GOG-0278
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Lymphedema, Stage IA1 Cervical Cancer AJCC v6 and v7, Stage IA2 Cervical Cancer AJCC v6 and v7
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 224 participants (estimated)
- Lead sponsor
- GOG FoundationResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 5 Jun 2013 (actual)
- Primary completion
- 1 Dec 2024 (estimated)
- Study completion
- 1 Dec 2025 (estimated)
- First posted
- 25 Jul 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial studies the physical function and quality-of-life before and after surgery in patients with stage I cervical cancer. Studying quality-of-life in patients undergoing surgery for cervical cancer may help determine the intermediate-term and long-term effects of surgery.
Detailed description
PRIMARY OBJECTIVES:
- To examine the changes before and after non-radical surgical treatment (simple hysterectomy or cone biopsy [fertility preservation] and pelvic lymphadenectomy) on functional outcomes of bladder, bowel, and sexual function for stage IA1 (lymphatic vessel invasion positive [LVSI+]) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
II. To evaluate incidence and severity of lymphedema after non-radical surgery (simple hysterectomy or cone biopsy [fertility preservation] and pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
SECONDARY OBJECTIVES:
- To investigate if non-radical surgery (simple hysterectomy or cone biopsy [fertility preservation] with pelvic lymphadenectomy) demonstrates greater physical function and less toxicity in comparison to historical data on radical surgery (radical hysterectomy or radical trachelectomy).
II. To evaluate incidence and severity of treatment-related adverse events, including surgical complications, among the entire cohort and by treatment type.
III. To evaluate changes in quality of life (QOL) (Functional Assessment of Cancer Therapy-Cervix [FACT-Cx]), cancer worries (Impact of Events Scale [IES]) and sexual (Female Sexual Function Index [FSFI])/reproductive concerns (RCS) among the entire cohort and by treatment type.
IV. To explore relationships (correlation, interaction, independence) between functional outcomes (i.e., bladder function, bowel function, sexual function), adverse events (including and surgical complication lymphedema [Gynecologic Cancer Lymphedema Questionnaire (GCLQ)]), cancer worry (IES), surgical complications, and overall quality of life (FACT-Cx).
- To determine participants' intention for conception \& fertility rates (Integrative Care for Fertility [ICF]) and assess the reproductive concerns (RCS) of women following cone biopsy and pelvic lymphadenectomy for stage IA1 (LVSI+) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
VI. To estimate the efficacy of non-radical surgery (simple hysterectomy or cone biopsy [fertility preservation] and pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (=< 2 cm) carcinoma of the cervix.
OUTLINE:
Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
Patients complete the FACT-Cx, the IES, the FSFI, the GCLQ, and the Patient Reported Outcomes Measurement Information System (PROMIS) questionnaires at baseline, 4-6 weeks after surgery, and then every 6 months for 3 years. Patients undergoing cone biopsy and pelvic lymphadenectomy also complete the ICF and RCS questionnaires.
After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months for 1 year, and then every 6 months for 2 years.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment (cone biopsy/lymphadenectomy or hysterectomy) | Experimental | Procedure: Conization, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Therapeutic Conventional Surgery, Procedure: Therapeutic LymphadenectomyPatients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patient must consent for the appropriate surgery
- Patients with a histologic diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix, stage IA1 (lymph-vascular space invasion [LVSI]+), IA2, and IB1 (tumor size [maximum visible or palpable]) =< 2 cm), any grade
- All patients must have undergone a cone biopsy or loop electrosurgical excision procedure (LEEP); depth of invasion must be =< 10 mm
- Patients must have no evidence of metastasis on positron emission tomography (PET) scan or magnetic resonance imaging (MRI) or computed tomography (CT) scan of the pelvis and chest imaging
- Patients who have met the pre-entry requirements
Key exclusion criteria (6 listed)
- Patients with stage IA1 disease who are LVSI negative
- Patients with stage IB1 with tumor size (maximum visible or palpable) > 2 cm
- Patients with >= stage IB2 disease
- Patients with clear cell or neuroendocrine cell types
- Patients with depth of invasion > 10 mm on first cone biopsy (or LEEP)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ConizationAlso: cone biopsy, Cone Biopsy of Cervix, Conization of Cervix, Conization of Uterine CervixUndergo cone biopsy | Procedure or surgery | Treatment (cone biopsy/lymphadenectomy or hysterectomy) |
| Quality-of-Life AssessmentAlso: Quality of Life AssessmentAncillary studies | Other | Treatment (cone biopsy/lymphadenectomy or hysterectomy) |
| Questionnaire AdministrationAncillary studies | Other | Treatment (cone biopsy/lymphadenectomy or hysterectomy) |
| Therapeutic Conventional SurgeryUndergo hysterectomy | Procedure or surgery | Treatment (cone biopsy/lymphadenectomy or hysterectomy) |
| Therapeutic LymphadenectomyUndergo lymphadenectomy | Procedure or surgery | Treatment (cone biopsy/lymphadenectomy or hysterectomy) |
Primary outcome
Change in bladder and bowel function score based on supplemental bladder and bowel questions plus 4 items from the Functional Assessment of Cancer Therapy-Cervix (3 bladder and 1 bowel question)
Time frame: Baseline to 3 years
Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Change in sexual function and activity based on Female Sexual Function Index (19 items) score plus 2 Patient Reported Outcomes Measurement Information System screener items
Time frame: Baseline to 3 years
Analysis of variance methods with repeated measurements and a time component will initially be used to determine whether there are significant changes over time.
Lymphedema
Time frame: Up to 3 years
Based on Cancer Lymphedema Questionnaire score.
Maximum grade and duration of severe adverse events associated with bladder, bowel, and sexual dysfunction and lymphedema
Time frame: Up to 3 years after non-radical surgical procedure
Graded according to Common Terminology Criteria for Adverse Events version 4.0 (version 5.0 will be used staring April 1, 2018).
7 secondary outcomes
Maximum grade of treatment-related adverse events
Time frame: Up to 30 days after surgical procedure
Change in overall quality of life
Time frame: Baseline to 3 years
Change in cancer worries based on Impact of Events score
Time frame: Baseline to 3 years
Change in reproductive concerns based on reproductive concerns (14 items) score
Time frame: Baseline to 3 years
Site of first recurrence
Time frame: Up to 3 years
Recurrence-free survival
Time frame: Up to 3 years
Overall survival
Time frame: Up to 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 May 2024.
- Derived from this study: PubMed 37650664Boisen M, Guido R. Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer. Clin Obstet Gynecol. 2023 Sep 1;66(3):500-515. doi: 10.1097/GRF.0000000000000790. Epub 2023 Jul 25.
Related trials for Cervical Adenocarcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Allan L Covens principal investigator
NRG Oncology
185 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Conization, Quality-of-Life Assessment and Questionnaire Administration in people with Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma, run by GOG Foundation at 185 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 185 sites in United States, South Korea, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in bladder and bowel function score based on supplemental bladder and bowel questions plus 4 items from the Functional Assessment of Cancer Therapy-Cervix (3 bladder and 1 bowel question) (time frame: Baseline to 3 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01649089, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 May 2024.